Multiple Myeloma News & Features
Patients with multiple myeloma seem to have improves survival if they are found to have monoclonal gammopathy of undetermined significance (MGUS) first.
Drug is now sanctioned for people who have received at least two prior standard therapies.
The FDA has approved Farydak (panobinostat) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma.
Celgene received FDA approval to expand the indications for lenaliodomide (Revlimid) to include treatment of newly diagnosed multiple myeloma.
Magnetic resonance imaging (MRI) is gold standard for imaging axial skeleton, assessing painful lesions, and identification of benign fractures.
Multiple Myeloma Clinical Trials
- Angelina Jolie has ovaries, fallopian tubes removed over cancer concerns
- Drug sequence with gemcitabine
- Breast cancer metastasis may be tied to cell that regulates blood flow
- Radiation plus immunotherapy revs up immune system to better attack melanoma
- Active surveillance of intermediate-risk prostate cancer associated with decreased survival
- Repeated courses of certain antibiotics associated with increased diabetes risk
- Dramatic rise in high blood pressure contributes to many U.S. deaths
- More alcohol consumption increases risk of liver cancer, but coffee is protective
- Urine test may detect kidney cancer early
- Intervention improves hand hygiene practice for nurses
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|